Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Badesch

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Chest|January 21, 2019
Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel ReportJames R Klinger, C Gregory Elliott, Deborah J Levine, et al.
Chest|June 19, 2010
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary RegistriesAdaani E Frost, David B Badesch, Robyn J Barst, et al.
Circulation|June 30, 2010
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)Raymond L Benza, Dave P Miller, Mardi Gomberg-Maitland, et al.
Chest|June 18, 2014
Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel reportDarren B Taichman, Joe Ornelas, Lorinda Chung, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 15, 2003
Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamicsWilliam T Abraham, Mary V Raynolds, David B Badesch, et al.
Journal of the American College of Cardiology|November 14, 2009
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertensionRonald J Oudiz, Nazzareno Galiè, Horst Olschewski, et al.
American Heart Journal|January 21, 2014
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized studyKelly M Chin, David B Badesch, Ivan M Robbins, et al.
Chest|October 17, 2014
Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational studyRobert P Frantz, Robert J Schilz, Murali M Chakinala, et al.
Circulation|May 29, 2008
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Nazzareno Galiè, Horst Olschewski, Ronald J Oudiz, et al.
Journal of the American College of Cardiology|June 27, 2009
End points and clinical trial design in pulmonary arterial hypertensionVallerie V McLaughlin, David B Badesch, Marion Delcroix, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Chest|January 21, 2019
Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel ReportJames R Klinger, C Gregory Elliott, Deborah J Levine, et al.
Chest|June 19, 2010
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary RegistriesAdaani E Frost, David B Badesch, Robyn J Barst, et al.
Circulation|June 30, 2010
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)Raymond L Benza, Dave P Miller, Mardi Gomberg-Maitland, et al.
Chest|June 18, 2014
Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel reportDarren B Taichman, Joe Ornelas, Lorinda Chung, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 15, 2003
Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamicsWilliam T Abraham, Mary V Raynolds, David B Badesch, et al.
Journal of the American College of Cardiology|November 14, 2009
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertensionRonald J Oudiz, Nazzareno Galiè, Horst Olschewski, et al.
American Heart Journal|January 21, 2014
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized studyKelly M Chin, David B Badesch, Ivan M Robbins, et al.
Chest|October 17, 2014
Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational studyRobert P Frantz, Robert J Schilz, Murali M Chakinala, et al.
Circulation|May 29, 2008
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Nazzareno Galiè, Horst Olschewski, Ronald J Oudiz, et al.
Journal of the American College of Cardiology|June 27, 2009
End points and clinical trial design in pulmonary arterial hypertensionVallerie V McLaughlin, David B Badesch, Marion Delcroix, et al.
Pageof 9